OBJECTIVE: The associations of the CA125 regression rate with initial response to chemotherapy and prognosis remain unclear. We examined the association between CA125 regression in neoadjuvant chemotherapy (NAC) and prognosis. METHODS: Fifty patients with advanced ovarian cancer (TNM classification TIIIc or M1) who received initial NAC and did not undergo significant cytoreductive surgery were selected for the retrospective analysis, after excluding clear cell carcinoma and mucinous adenocarcinoma putative to be cisplatin-resistant. For each patient, regression coefficient was calculated using all the CA125 levels measured from the day of NAC as day 0 until the day of normalization of CA125 level (<35 IU/ml) or the day of standard surgery. Responder was defined as a regression coefficient of -0.039 or greater (33 cases) and nonresponder as a regression coefficient less than -0.039 (17 cases). RESULTS: The 3-year survival rate for all 50 cases was 59.3%. When stratified by regression coefficient of CA125 levels, the 3-year survival was 70.5% in responders and 43.3% in nonresponders. Univariate analysis identified the regression coefficient of CA125 as a significant prognostic factor for overall survival (P = 0.012; log lank test). Residual tumor at standard surgery after NAC and absolute CA125 level were not significant prognostic factors. CONCLUSIONS: Based on the CA125 regression rate, it is possible to stratify TIIIc or M1 ovarian serous adenocarcinoma cases into those with a good prognosis of survival and those with poor prognosis. Regression coefficient of CA125 level greater than -0.039 predicts good 3-year survival after subsequent radical surgeries.
OBJECTIVE: The associations of the CA125 regression rate with initial response to chemotherapy and prognosis remain unclear. We examined the association between CA125 regression in neoadjuvant chemotherapy (NAC) and prognosis. METHODS: Fifty patients with advanced ovarian cancer (TNM classification TIIIc or M1) who received initial NAC and did not undergo significant cytoreductive surgery were selected for the retrospective analysis, after excluding clear cell carcinoma and mucinous adenocarcinoma putative to be cisplatin-resistant. For each patient, regression coefficient was calculated using all the CA125 levels measured from the day of NAC as day 0 until the day of normalization of CA125 level (<35 IU/ml) or the day of standard surgery. Responder was defined as a regression coefficient of -0.039 or greater (33 cases) and nonresponder as a regression coefficient less than -0.039 (17 cases). RESULTS: The 3-year survival rate for all 50 cases was 59.3%. When stratified by regression coefficient of CA125 levels, the 3-year survival was 70.5% in responders and 43.3% in nonresponders. Univariate analysis identified the regression coefficient of CA125 as a significant prognostic factor for overall survival (P = 0.012; log lank test). Residual tumor at standard surgery after NAC and absolute CA125 level were not significant prognostic factors. CONCLUSIONS: Based on the CA125 regression rate, it is possible to stratify TIIIc or M1 ovarian serous adenocarcinoma cases into those with a good prognosis of survival and those with poor prognosis. Regression coefficient of CA125 level greater than -0.039 predicts good 3-year survival after subsequent radical surgeries.
Authors: Richard G Moore; Michael Craig Miller; Margaret M Steinhoff; Steven J Skates; Karen H Lu; Geralyn Lambert-Messerlian; Robert C Bast Journal: Am J Obstet Gynecol Date: 2011-12-30 Impact factor: 8.661
Authors: Naveen S Vasudev; Ioannis Trigonis; David A Cairns; Geoff D Hall; David P Jackson; Timothy Broadhead; John Buxton; Richard Hutson; David Nugent; Timothy J Perren Journal: Arch Gynecol Obstet Date: 2010-08-29 Impact factor: 2.344
Authors: Maria Lee; Min Young Chang; Hanna Yoo; Kyung Eun Lee; Doo Byung Chay; Hanbyoul Cho; Sunghoon Kim; Young Tae Kim; Jae-Hoon Kim Journal: Yonsei Med J Date: 2016-05 Impact factor: 2.759
Authors: Yong Jae Lee; In Ha Lee; Yun-Ji Kim; Young Shin Chung; Jung-Yun Lee; Eun Ji Nam; Sunghoon Kim; Sang Wun Kim; Young Tae Kim Journal: PLoS One Date: 2018-09-06 Impact factor: 3.240